Curaleaf Holdings (CURLF) Capital Expenditures (2019 - 2024)
Curaleaf Holdings (CURLF) recorded quarterly Capital Expenditures of $158.0 million in Q4 2024, up 668.47% quarter-over-quarter from -$27.8 million in Q3 2024, and up 205.97% on a YoY basis from $51.6 million in Q1 2024.
Curaleaf Holdings (CURLF) Capital Expenditures (2019 - 2024) Analysis & Trends
Curaleaf Holdings' Capital Expenditures history runs 6 years deep, the most recent figure standing at $158.0 million for Q4 2024.
- In Q4 2024, Capital Expenditures rose 205.97% year-over-year to $158.0 million; the TTM figure through Dec 2024 stood at $166.5 million (down 24.77% YoY), while the FY2025 annual figure was $2.8 million, down 97.01% from the prior year.
- Capital Expenditures was $158.0 million for Q4 2024 at Curaleaf Holdings, up from -$27.8 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $239.6 million in Q4 2022 to a low of -$54.6 million in Q4 2021.
- Historically, Capital Expenditures has averaged $78.3 million across 5 years, with a median of $51.6 million in 2023.
- The sharpest annual moves came in 2021 and 2022: Capital Expenditures sank 127.79% in 2021, then surged 538.92% in 2022.
- A 5-year view of Capital Expenditures shows it stood at $196.5 million in 2020, then slumped by 127.79% to -$54.6 million in 2021, then soared by 538.92% to $239.6 million in 2022, then slumped by 78.45% to $51.6 million in 2023, then soared by 205.97% to $158.0 million in 2024.
- The last three Capital Expenditures figures came in at $158.0 million (Q4 2024), -$27.8 million (Q3 2024), and $51.6 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 168.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 110.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 100.80 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 9.10 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 51.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 4.09 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 2.04 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 8.83 Mn |
| 10 | Curaleaf Holdings | - | - | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 158.00 Mn |
| Dec 31, 2024 | 158.00 Mn |
| Sep 30, 2024 | -27.79 Mn |
| Sep 30, 2024 | -27.79 Mn |
| Dec 31, 2023 | 51.64 Mn |
| Dec 31, 2023 | 51.64 Mn |
| Sep 30, 2023 | -15.36 Mn |
| Sep 30, 2023 | -15.36 Mn |
| Dec 31, 2022 | 239.63 Mn |
| Dec 31, 2022 | 239.63 Mn |
| Dec 31, 2021 | -54.59 Mn |
| Dec 31, 2021 | -54.59 Mn |
| Dec 31, 2020 | 196.47 Mn |
| Dec 31, 2020 | 196.47 Mn |
| Dec 31, 2019 | 148.93 Mn |
| Dec 31, 2019 | 148.93 Mn |